tetano
Editor, Senior Moderator
Life Sci
. 2021 Aug 2;119871.
doi: 10.1016/j.lfs.2021.119871. Online ahead of print.
Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases
Madhur D Shastri[SUP] 1 [/SUP], Venkata Sita Rama Raju Allam[SUP] 2 [/SUP], Shakti D Shukla[SUP] 3 [/SUP], Niraj Kumar Jha[SUP] 4 [/SUP], Keshav Raj Paudel[SUP] 5 [/SUP], Gregory M Peterson[SUP] 6 [/SUP], Rahul P Patel[SUP] 6 [/SUP], Philip M Hansbro[SUP] 5 [/SUP], Dinesh K Chellappan[SUP] 7 [/SUP], Kamal Dua[SUP] 8 [/SUP]
Affiliations
Abstract
Non-communicable, chronic respiratory diseases (CRDs) affect millions of individuals worldwide. The course of these CRDs (asthma, chronic obstructive pulmonary disease, and cystic fibrosis) are often punctuated by microbial infections that may result in hospitalization and are associated with increased risk of morbidity and mortality, as well as reduced quality of life. Interleukin-13 (IL-13) is a key protein that regulates airway inflammation and mucus hypersecretion. There has been much interest in IL-13 from the last two decades. This cytokine is believed to play a decisive role in the exacerbation of inflammation during the course of viral infections, especially, in those with pre-existing CRDs. Here, we discuss the common viral infections in CRDs, as well as the potential role that IL-13 plays in the virus-induced disease pathogenesis of CRDs. We also discuss, in detail, the immune-modulation potential of IL-13 that could be translated to in-depth studies to develop IL-13-based therapeutic entities.
Keywords: Asthma; COPD; COVID; Chronic respiratory diseases (CRDs); Cystic fibrosis; Eosinophils; IL-13; IL-33; Innate lymphoid cells (ILC2s).
. 2021 Aug 2;119871.
doi: 10.1016/j.lfs.2021.119871. Online ahead of print.
Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases
Madhur D Shastri[SUP] 1 [/SUP], Venkata Sita Rama Raju Allam[SUP] 2 [/SUP], Shakti D Shukla[SUP] 3 [/SUP], Niraj Kumar Jha[SUP] 4 [/SUP], Keshav Raj Paudel[SUP] 5 [/SUP], Gregory M Peterson[SUP] 6 [/SUP], Rahul P Patel[SUP] 6 [/SUP], Philip M Hansbro[SUP] 5 [/SUP], Dinesh K Chellappan[SUP] 7 [/SUP], Kamal Dua[SUP] 8 [/SUP]
Affiliations
- PMID: 34352260
- DOI: 10.1016/j.lfs.2021.119871
Abstract
Non-communicable, chronic respiratory diseases (CRDs) affect millions of individuals worldwide. The course of these CRDs (asthma, chronic obstructive pulmonary disease, and cystic fibrosis) are often punctuated by microbial infections that may result in hospitalization and are associated with increased risk of morbidity and mortality, as well as reduced quality of life. Interleukin-13 (IL-13) is a key protein that regulates airway inflammation and mucus hypersecretion. There has been much interest in IL-13 from the last two decades. This cytokine is believed to play a decisive role in the exacerbation of inflammation during the course of viral infections, especially, in those with pre-existing CRDs. Here, we discuss the common viral infections in CRDs, as well as the potential role that IL-13 plays in the virus-induced disease pathogenesis of CRDs. We also discuss, in detail, the immune-modulation potential of IL-13 that could be translated to in-depth studies to develop IL-13-based therapeutic entities.
Keywords: Asthma; COPD; COVID; Chronic respiratory diseases (CRDs); Cystic fibrosis; Eosinophils; IL-13; IL-33; Innate lymphoid cells (ILC2s).